Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil

The transcription factor NRF2 is constitutively active in glioblastoma, a highly aggressive brain tumor subtype with poor prognosis. Temozolomide (TMZ) is the primary chemotherapeutic agent for this type of tumor treatment, but resistance to this drug is often observed. This review highlights the re...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Karoline Almeida Lima, Isabeli Yumi Araújo Osawa, Maria Carolina Clares Ramalho, Izadora de Souza, Camila Banca Guedes, Cláudio Henrique Dahne de Souza Filho, Linda Karolynne Seregni Monteiro, Marcela Teatin Latancia, Clarissa Ribeiro Reily Rocha
Format:	Artigo
Sprog:	Inglês
Udgivet:	MDPI AG 2023-04-01
Serier:	Biomedicines
Fag:	NRF2 glioblastoma temozolomide
Online adgang:	https://www.mdpi.com/2227-9059/11/4/1081
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!